Liver resection for hepatocellular carcinoma with tumor thrombus in hepatic vein, vena cava, and atrium: Long-term prognosis

2003 ◽  
Vol 124 (4) ◽  
pp. A695 ◽  
Author(s):  
Junichi Yamanaka ◽  
Yuji Iimuro ◽  
Hiroki Kanno ◽  
Nobukazu Kuroda ◽  
Tadamichi Hirano ◽  
...  
2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 371-371
Author(s):  
Takashi Kokudo ◽  
Kiyoshi Hasegawa ◽  
Yutaka Matsuyama ◽  
Tadatoshi Takayama ◽  
Namiki Izumi ◽  
...  

371 Background: Because of the rarity of hepatic vein tumor thrombus (HVTT), compared with portal vein tumor thrombus (PVTT), in patients with hepatocellular carcinoma (HCC), little is known about this disease entity. The aim of this study was to evaluate the prognosis of each treatment modality for HVTT through an analysis of data collected in a Japanese nationwide survey. Methods: We analyzed data for 1,021 Child-Pugh A HCC patients with HVTT without inferior vena cava invasion registered between 2000 and 2007. Of these patients, 540 patients who underwent liver resection (LR) and 481 patients who received other treatments were compared. The propensity scores were calculated and we successfully matched 244 patients (52.5% of the LR group). Results: The median survival time (MST) in the LR group was 2.89 years longer than that in the non-LR group (4.47 years vs 1.58 years; P < 0.001) and 1.17 years longer than that in the non-LR group (2.93 years vs 1.76 years; P = 0.009) in a propensity score-matched cohort. After curative resection, the MSTs were similar between patients with HVTT in the peripheral hepatic vein and those with HVTT in the major hepatic vein (4.85 years vs 4.67 years; P = 0.974). In the LR group, the postoperative 90-day mortality rate was 3.4% (16patients). In patients without PVTT, the MST was significantly better than that in patients with PVTT (5.67 years vs. 1.88 years; P < 0.001). Conclusions: LR is associated with a good prognosis in HCC patients with HVTT, especially in patients without PVTT.


Liver Cancer ◽  
2021 ◽  
Author(s):  
Ryota Matsuki ◽  
Naohiro Okano ◽  
Takaaki Arai ◽  
Shinya Yoshiike ◽  
Masaharu Kogure ◽  
...  

Abstract Recent developments in systemic chemotherapy for advanced hepatocellular carcinoma have been outstanding. However, reports on conversion surgery after lenvatinib therapy are scarce. We present the first case of advanced hepatocellular carcinoma with tumor thrombus in the suprahepatic vena cava close to the right atrium, which shrank after 12 weeks’ administration of lenvatinib, thereby leading to successful conversion surgery without using total vascular exclusion or extracorporeal circulation. The treatment strategy for hepatocellular carcinoma with macroscopic hepatic vein tumor thrombus is controversial, however, from a Japanese nationwide survey, surgical resection has been accepted as one of the treatment options for advanced hepatocellular carcinoma with hepatic vein tumor thrombus in Japan. However, the survival rate after resection of hepatocellular carcinoma having inferior vena cava tumor thrombus with extracorporeal circulation was reported to be worse than without extracorporeal circulation, and some preoperative down-sizing therapy for inferior vena cava tumor thrombus was advocated. Preoperative lenvatinib therapy might be a promising option among the multidisciplinary treatments for hepatocellular carcinoma with macroscopic tumor thrombus in the hepatic veins.


HPB ◽  
2018 ◽  
Vol 20 ◽  
pp. S412
Author(s):  
S. Mori ◽  
T. Aoki ◽  
T. Shimizu ◽  
K. Tani ◽  
K.H. Park ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document